Light at end of the tunnel?
This article was originally published in The Rose Sheet
Market research firm has good news and bad news regarding consumer attitudes in the current economy. On NPD's Economy Tracker scale of 0 ("Very Concerned") to 100 ("Very Confident"), consumers' "general economic perception" score has dropped from 38 in October to 36.7 in February. With that drop of less than two points, consumers' intention to spend has fallen more than 5 points, NPD notes. However, consumer concern for job security appears to be leveling off - with 34% "very concerned" about job security and/or income in February, versus 36% the month before and 38% in December - "which could mean they are preparing to spend again," firm says. Marshal Cohen, chief industry analyst at NPD, states: "Of all the data I look at, this measure provides one of the best indications of how consumers are going to behave. February's results show consumers feeling better on this front and could signal consumer stabilization, a point at which consumers catch their breath, reassess and prioritize their purchase needs in preparation to begin spending again." NPD's Economy Tracker delivers monthly reports and a year-end analysis based on online surveys completed by consumers nationwide
You may also be interested in...
Supplement industry stakeholders say proposal could reveal helpful information about consumers’ regard for VMS products. But until the questions FDA will ask in interviews are known, it’s not clear whether the information collection might sow doubt about the products.
A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.